CBP501 Clinical Trials (2026): 5 Studies for Solid Tumors & Advanced Solid Tumors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 CBP501 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Solid Tumors & Advanced Solid Tumors) and 395 total planned enrollment. Most recent activity: NCT04953962 (Apr 2023).
CBP501 clinical trials at a glance: phase × recruitment status
| Phase | completed | Total |
|---|---|---|
| P1 | 2 | 2 |
| P1/P2 | 1 | 1 |
| P2 | 2 | 2 |
CBP501 clinical trials by indication
Pancreatic Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04953962 | — | P2 | completed | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03113188 | CBP501 | P1 | completed | CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors |
Metastatic Non-squamous Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00942825 | CBP08-02 | P2 | completed | Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) |
Malignant Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00700336 | — | P1/P2 | completed | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) |
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00551512 | — | P1 | completed | Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors |
CBP501 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CBP08-02 | NCT00942825 | P2 | completed | Metastatic Non-squamous Non Small Cell Lung Cancer | 195 | PMID 17237275 |
All CBP501 trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04953962 | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | P2 | completed | 36 | CanBas Co. Ltd. | Dec 2021 | |
| NCT03113188 | CBP501 | CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors | P1 | completed | 47 | CanBas Co. Ltd. | Oct 2017 |
| NCT00942825 | CBP08-02 | Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) | P2 | completed | 195 | CanBas Co. Ltd. | Apr 2009 |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | P1/P2 | completed | 69 | CanBas Co. Ltd. | May 2008 | |
| NCT00551512 | Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors | P1 | completed | 48 | CanBas Co. Ltd. | Nov 2006 |
CBP501 clinical trials: frequently asked questions
- How many CBP501 clinical trials are there?
- 5 CBP501 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are marked completed.
- Are CBP501 clinical trials recruiting in 2026?
- No active CBP501 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is CBP501 being studied for?
- CBP501 is being studied for Solid Tumors, Advanced Solid Tumors, Cancer, Malignant Pleural Mesothelioma, Metastatic Non-squamous Non Small Cell Lung Cancer and 1 more. The trials are grouped by indication on this page.
- What phase is CBP501 in?
- CBP501 clinical trials span 2 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CBP501 clinical trials?
- The lead sponsor across the most CBP501 trials is CanBas Co. Ltd.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CBP501as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: